AzTrials
AzTrials

Obesity, AbdominalNCT03805516

Central Obesity and Cancer Prevention for Chinese American Women

A study testing SCOPP-CW in people with Obesity, Abdominal and Cancer Prevention, run by San Francisco State University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This project examines the feasibility of a smartphone-based intervention to reduce obesity and breast cancer risk among Chinese American women in San Francisco. The proposed intervention is to use the mobile application and an activity tracker device to promote a healthier lifestyle and physical activity. Read more about this study

Who is it for?
Ages 18 years and older, women onlyHealthy volunteers can take part
Conditions the study is for
Obesity, Abdominal, Cancer Prevention
What is being tested?
SCOPP-CW
Could I receive a placebo?
No, everyone receives an active treatment
How many people
18 participants
Where
1 siteUnited States
Study dates
16 Oct 2019to 31 Aug 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • be female
  • be at least 18 years old
  • have a waist circumference great than 80 cm
  • own a smartphone
  • be able to read Chinese and speak Mandarin
  • be premenopausal
  • have a child between the age of 1 and 18 years old.

Who cannot join

  • are pregnant
  • gave birth less than 12 months prior to enrollment date
  • have a history of breast cancer
  • have an acute or life-threatening disease (e.g., renal failure).

Trial locations and contacts

1 site in 1 country.

United States1 site
  • San Francisco State University

    San Francisco, California, 94132

Other trials in United States

About this study

This project examines the feasibility of a smartphone-based intervention to reduce obesity and breast cancer risk among Chinese American women in San Francisco. The proposed intervention is to use the mobile application and an activity tracker device to promote a healthier lifestyle and physical activity. Ultimately, the findings will advance the NIH mission of enhancing health promotion and disease prevention.

Read the detailed description

Cancer is the leading cause of death in women in the United States (US). Chinese Americans are the largest ethnic group among Asian Americans. Although the incidence of breast cancer, the most common cancer in women, has decreased among other U.S racial groups over the last 15 years, Chinese American women in California have experienced a significant increase of incidence of 1.1% from 1998 to 2013. Studies have found that assimilation stress and obesity are associated with increased risk for breast cancer in Chinese American women. There are no existing interventions targeted at breast cancer prevention among premenopausal mothers with abdominal obesity. Interventions tailored to an individual's cultural, lifestyle and social support system are needed to reduce obesity and breast cancer risk. A smartphone-based intervention provides a promising platform for obesity and cancer prevention. The overall goal of this project is to test the feasibility of an obesity and breast cancer prevention intervention among Chinese American women in San Francisco. The investigators will adapt the Healthy Mothers Healthy Children: Technology-Based Intervention to Prevent Obesity to reduce obesity and breast cancer risk in premenopausal women with abdominal obesity who have dependent children in San Francisco. The proposed intervention ("Smartphone-Based Cancer and Obesity Prevention Program for Chinese Women: SCOPP-CW) includes 12 weekly educational modules and six bi-weekly tailored messages delivered via WeChat, a popular private communication app used by Chinese and Chinese Americans. The investigators propose to conduct a pilot randomized control study (RCT) to assess the short-term efficacy of SCOPP-CW on abdominal obesity, breast cancer knowledge and attitudes, weight-related behaviors (food intake and physical activity), and metabolic risk (blood pressure, lipid profile, hemoglobin A1c), which are associated with breast cancer. Thus the investigators propose the following aims: (1) Aim 1: To estimate the preliminary efficacy of the SCOPP-CW intervention on the primary outcomes (i.e. waist circumference and breast cancer knowledge and attitudes) and secondary outcomes (i.e. body mass index, self-efficacy, food intake, physical activity at baseline, 3 months, and 6 months, and metabolic risk [blood pressure, hemoglobin A1C, and lipid panel]) at baseline and 6 months.

Aim 2: To assess feasibility by understanding participants' acceptance, barriers to adherence and recommendations for intervention using focus group interviews. The investigators anticipate that this intervention will have a significant impact on breast cancer prevention. The investigators plan to use the proposed pilot study's findings to conduct a larger scale randomized trial (R01) to test the long-term efficacy of the intervention.

Being tested
SCOPP-CW, Control
Medical subject headings
Obesity, Abdominal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SCOPP-CWBehavioural

    The proposed intervention integrates the Social Cognitive Theory, use of everyday technology (WeChat), and an adaptation of an evidence-based program that is tailored to the behavior patterns, preferences, and cultures of premenopausal Chinese American women. The intervention includes three components: (1) daily tracking of physical activities, (2) 12 weekly educational modules on healthy lifestyle, physical activity, and breast cancer prevention, and (3) 6 bi-weekly tailored messages to include tips for lifestyle modification, stress management, and healthy weight maintenance based on the user's personal characteristics and behavior patterns.

  • ControlBehavioural

    This is the comparative/control group for the intervention. The control group receives daily tracking of physical activity and 12 weekly non-tailored educational information on general health topics.

Study groups in NCT03805516
Study groupRoleWhat they receive
InterventionExperimental1. . Daily use of a Fitbit Alta HRTM to identify behavior patterns. 2. 12 weekly SCOPP-CW educational modules delivered via WeChat. 3. 6 bi-weekly WeChat tailored messages based on based on the participant's tracker information, personal goals, and preferences
Receives: Behavioral: SCOPP-CW
ControlActive comparator1. . Daily use of a Fitbit Alta HRTM to identify behavior patterns. 2. 12 weekly non-tailored educational modules on general health topics delivered via WeChat.
Receives: Behavioral: Control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. waist circumference

    waist measured in centimeters by NIH waist circumference measurement protocol

    Measured: Change from baseline waist measurement at 3 months and 6 months

  2. breast cancer knowledge and attitudes

    13-item self-report questionnaire measuring knowledge, attitude, and practice of breast cancer screening

    Measured: Change from baseline breast cancer screening knowledge score at 3 months and 6 months

Secondary outcomes (8)
  1. body mass index

    Weight and height (weight [kg]/height [m])

    Measured: change from baseline BMI at 3 months and 6 months

  2. self-efficacy

    28-item self-report survey measuring self-efficacy on nutrition, stress management, physical activity

    Measured: Change from baseline self-efficacy questionnaire score at 3 months and 6 months

  3. food intake

    Chinese food frequency questionnaire (FFQ) includes 118 food items

    Measured: Change from baseline food frequency at 3 months and 6 months

  4. physical activity

    Daily tracking 10 hours awake time with a Fitbit device

    Measured: Change from baseline daily physical activity at 3 months and 6 months

  5. blood pressure

    Systolic and diastolic blood pressure measured in mmHg

    Measured: Change from baseline blood pressure at 3 months and 6 months

  6. Hemoglobin A1C

    Glycated hemoglobin to measure average level of blood sugar

    Measured: Change from baseline hemoglobin A1C at 6 months

  7. Lipid panel

    A blood test that measures the level of different types of fat (lipid molecules) in the blood

    Measured: Change from baseline lipid panel at 6 months

  8. C-reactive protein

    A blood test that measure the presence of inflammation in the body

    Measured: Change from baseline lipid panel at 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jan 2019
  2. Study start16 Oct 2019
  3. Primary completion31 Aug 2021
  4. Study completion31 Aug 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
18 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03805516
Sponsor's protocol ID
20429001
Status last verified
Nov 2023
First submitted
9 Jan 2019
Last updated
30 Nov 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing SCOPP-CW in people with Obesity, Abdominal and Cancer Prevention, run by San Francisco State University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

waist circumference (time frame: Change from baseline waist measurement at 3 months and 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in